Chemoradiation of cervical cancer cells: Targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7364-7371

  Koivusalo, Riku ^a,b   Krausz, Eberhard ^d   Ruotsalainen, Pertti ^a   Helenius, Hans ^c   Hietanen, Sakari ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; OXALIPLATIN; PROTEIN E6; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; UTERINE CERVIX CARCINOMA; VIRUS ONCOGENE; WART VIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HELA CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; PAPILLOMAVIRIDAE; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0037115548     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Rose, P. G. Chemoradiotherapy for cervical cancer. Eur. J. Cancer, 38: 270-278, 2002.
2. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189: 12-19, 1999.
3. Zur, H. H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. (Bethesda), 92: 690-698, 2000.
4. Michael, D., and Oren, M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev., 12: 53-59, 2002.
5. Hietanen, S., Lain, S., Krausz, E., Blattner, C., and Lane, D. P. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. USA, 97: 8501-8506, 2000.
6. Hengstermann, A., Linares, L. K., Ciechanover, A., Whitaker, N. J., and Scheffner, M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. USA. 98: 1218-1223, 2001.
7. Butz, K., Denk, C., Ullmann, A., Scheffner, M., and Hoppe-Seyler, F. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. USA, 97: 6693-6697, 2000.
8. Goodwin, E. C., and DiMaio, D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl. Acad. Sci. USA, 97: 12513-12518, 2000.
9. Wallace-Brodeur, R. R., and Lowe, S. W. Clinical implications of p53 mutations. Cell. Mol. Life Sci., 55: 64-75, 1999.
10. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents [see comments]. J. Clin. Investig., 104: 263-269, 1999.
11. Chaney, S. G., and Vaisman, A. Specificity of platinum-DNA adduct repair. J. Inorg. Biochem., 77: 71-81, 1999.
12. Petersen. L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., and Bohr, V. A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Mol. Endocrinol., 17: 2597-2602, 1996.
13. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
14. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
15. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Freidberg, E. C., Evans, M. K., Taffe, B. G., et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
16. Scherer, S. J., Maier, S. M., Seifert, M., Hanselmann, R. G., Zang, K. D., Muller-Hermelink, H. K., Angel, P., Welter, C., and Schartl, M. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J. Biol. Chem., 275: 37469-37473, 2000.
17. Kelland, L. R. Preclinical perspectives on platinum resistance. Drugs, 59 (Suppl. 4): 1-8, 2000.
18. 2/M transition by p53. Oncogene, 20: 1803-1815, 2001.
19. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
20. Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 86: 189-199, 1996.
21. Song, S., Gulliver, G. A., and Lambert, P. F. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc. Natl. Acad. Sci. USA, 95: 2290-2295, 1998.
22. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene. 10: 1053-1059, 1995.
23. Butz, K., Whitaker, N., Denk, C., Ullmann, A., Geisen, C., and Hoppe-Seyler, F. Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene, 18: 2381-2386, 1999.
24. Lane, D. P., and Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med., 8: S38-S42, 2002.
25. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature (Lond.). 362: 849-852, 1993.
26. Pardo, F. S., Su, M., Borek, C., Preffer, F., Dombkowski, D., Gerweck, L., and Schmidt, E. V. Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance. Radiat. Res., 140: 180-185, 1994.
27. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
28. Pirollo, K. F., Bouker, K. B., and Chang, E. H. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs, 11: 419-432, 2000.
29. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
30. Blagosklonny, M. V. p53: An ubiquitous target of anticancer drugs. Int. J. Cancer. 98: 161-166, 2002.
31. Hietanen, S., Auvinen, E., Grénman, S., Lakkala, T., Sajantila, A., Klemi, P., and Mäenpää, J. Isolation of two keratinocyte cell lines derived from HPV-positive dysplastic vaginal lesions. Int. J. Cancer. 52: 391-398, 1992.
32. Lipinski, K. S., Djeha, A. H., Krausz, E., Lane, D. P., Searle, P. F., Mountain, A., and Wrighton, C. J. Tumour-specific therapeutic adenovirus vectors: Repression of transgene expression in healthy cells by endogenous p53. Gene Ther., 8: 274-281, 2001.
33. Brown, J. M., and Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res., 59: 1391-1399, 1999.
34. Hamalainen, H. K., Tubman, J. C., Vikman, S., Kyrola, T., Ylikoski, E., Warrington, J. A., and Lahesmaa, R. Identification and validation of endogenous reference genes for expression profiling of T helper cell differentiation by quantitative real-time RT-PCR. Anal. Biochem., 299: 63-70, 2001.
35. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res., 17: 6419, 1989.
36. Suhnel, J. Zero interaction response surfaces for combined-action assessment. Food Chem. Toxicol., 34: 1151-1153, 1996.
37. Tallarida, R. J. Dose-response analysis. In: Drug Synergism and Dose Effect Data-Analysis, pp. 21-39. Chapman & Hall/CRC Press, 2000.
38. Shaulian, E., Haviv, I., Shaul. Y., and Oren, M. Transcriptional repression by the C-terminal domain of p53. Oncogene, 10: 671-680, 1995.
39. Gong, J. G., Costanzo, A., Yang, H. Q., Melino, G., Kaelin, W. G., Jr., Levrero, M., and Wang, J. Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (Lond.). 399: 806-809, 1999.
40. Agami, R., Blandino, G., Oren, M., and Shaul, Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature (Lond.), 399: 809-813, 1999.
41. Yuan, Z. M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y. Y., Lu, H., Kharbanda, S., Weichselbaum, R., and Kufe, D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (Lond.), 399: 814-817, 1999.
42. Di Como, C. J., Gaiddon, C., and Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell Biol., 19: 1438-1449, 1999.
43. Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., and Blandino, G. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem., 275: 29503-29512, 2000.
44. Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., and Kaelin, W. G., Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol., 18: 6316-6324, 1998.
45. Prabhu, N. S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., and el Deiry, W. S. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol., 13: 5-9, 1998.
46. Park, J. S., Kim, E. J., Lee, J. Y., Sin, H. S., Namkoong, S. E., and Um, S. J. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer, 91: 822-827, 2001.
47. Fan, J., and Bertino, J. R. Modulation of cisplatinum cytotoxicity by p53: Effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56: 966-972, 1999.
48. Chaney, S. G., and Sancar, A. DNA repair: Enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. (Bethesda), 88: 1346-1360, 1996.
49. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond.), 404: 42-49, 2000.
50. Scherer, S. J., Welter, C., Zang, K. D., and Dooley, S. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem. Biophys. Res. Commun. 221: 722-728, 1996.
51. Warnick, C. T., Dabbas, B., Ford, C. D., and Strait, K. A. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J. Biol. Chem., 276: 27363-27370, 2001.
52. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexyl-amine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res., 59: 3968-3971, 1999.
53. Therrien, J. P., Drouin, R., Baril, C., and Drobetsky, E. A. Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc. Natl. Acad. Sci. USA. 96: 15038-15043, 1999.
54. Kao, S. Y., Lemoine, F. J., and Mariott, S. J. HTLV-1 Tax protein sensitizes cells to apoptotic cell death induced by DNA damaging agents. Oncogene, 19: 2240-2248, 2000.
55. Woynarowski, J. M., Faivre, S., Herzig, M. C., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., and Juniewicz, P. E. Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol., 58: 920-927, 2000.
56. Zamble, D. B., Jacks, T., and Lippard, S. J. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 95: 6163-6168, 1998.
57. Vennin, P., Hecquet, B., Poissonnier, B., Fournier, C., Lequint, A., Delobelle, A., and Demaille, M. C. Comparative study of intravenous and intraarterial cis-platinum on intratumoral platinum concentration in carcinoma of the cervix. Gynecol. Oncol., 32: 180-183, 1989.